Viridian Therapeutics (VRDN) Cash Flow: Operating & Free Cash Flow

Viridian Therapeutics Cash Flow Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for Viridian Therapeutics, Inc. (VRDN) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Operating Activities
Net Income	-342.60	-269.95	-237.73	-129.87	-129.87	-110.72	-41.87	-32.70	-26.51
Depreciation & Amortization	0.46	0.54	0.52	0.26	0.26	0.24	0.29	0.28	0.31
Deferred Income Tax	0.00	0.00	0.00	0.00	0.00	0.06	-0.43	-0.42	0.00
Stock Based Compensation	44.30	42.15	67.17	19.77	14.47	3.65	3.97	3.68	2.41
Change in Working Capital	23.03	9.60	-9.43	15.96	1.72	4.43	1.65	1.94	-4.47
Change in Accounts Receivable	0.00	0.10	0.00	0.35	0.35	0.10	-0.08	1.43	-1.44
Change in Inventory	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-57.80	-50.90
Change in Accounts Payable	6.56	-0.07	-12.04	11.52	11.52	-0.43	0.53	-0.34	-0.10
Change in Other Working Capital	0.26	9.57	2.62	0.26	-3.34	4.75	1.21	58.64	47.97
Other Operating Activities	-1.58	-14.66	-4.71	0.26	0.05	72.57	0.34	0.38	0.09
Net Cash from Operating Activities	-276.39	-232.32	-184.17	-93.84	-54.58	-29.78	-36.06	-26.84	-28.17
Investing Activities
Capital Expenditures	-0.50	-0.51	-0.90	-0.80	-0.34	-0.04	-0.08	-0.45	-0.25
Acquisitions	0.00	0.00	0.00	0.00	0.00	29.37	-28.31	0.00	1.28
Purchases of Investments	-579.28	-695.07	-407.88	-223.26	-223.26	-81.81	-32.69	-62.46	0.00
Sales/Maturities of Investments	542.21	466.93	314.53	108.94	108.94	2.00	61.00	33.00	0.00
Other Investing Activities	0.00	0.00	0.00	0.00	0.08	0.00	28.31	-29.46	1.28
Net Cash from Investing Activities	-37.56	-228.65	-94.25	-115.13	-74.29	-50.48	28.23	-29.91	1.03
Financing Activities
Debt Repayment	28.88	0.00	15.00	5.00	0.00	-8.57	-2.33	0.00	5.33
Common Stock Issued	366.99	453.66	125.07	291.87	295.75	25.10	2.48	44.53	48.57
Other Financing Activities	30.88	4.08	85.60	-22.51	-8.28	84.77	-0.08	-2.61	-1.43
Net Cash from Financing Activities	426.74	457.74	225.67	322.24	125.28	101.31	0.07	41.92	52.47
Summary
Net Change in Cash	112.79	-3.23	-52.75	113.28	-3.60	21.05	-7.76	-14.84	25.34
Cash at Beginning of Period	99.59	102.83	155.58	42.30	45.90	24.85	32.61	47.44	22.10
Cash at End of Period	212.38	99.59	102.83	155.58	42.30	45.90	24.85	32.61	47.44
Free Cash Flow	-276.89	-232.83	-185.07	-94.64	-54.92	-29.82	-36.14	-27.29	-28.41
Supplemental Disclosures
Interest Paid	-	1.82	0.89	0.29	-	0.27	-	-	-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Viridian Therapeutics Cash Flow

What is Viridian Therapeutics's free cash flow?

Viridian Therapeutics had negative free cash flow of $276.89M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$276.39M minus $495.00K of capital expenditures.

How much does Viridian Therapeutics spend on capital expenditures?

Viridian Therapeutics spent $495.00K on capital expenditures in fiscal 2025, compared with $511.00K a year earlier.

Does Viridian Therapeutics pay dividends or buy back shares?

Viridian Therapeutics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition